Herceptin in the treatment of disseminated HER2-positive gastric cancer. Clinical case of successful treatment of elderly patient
- Authors: Besova N.S1, Khokhlova S.V1, Gorbunova V.A1
-
Affiliations:
- Issue: No 18 (2012)
- Pages: 75-79
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/280012
- ID: 280012
Cite item
Open Access
Access granted
Abstract
Disseminated gastric cancer (GC) is moderately sensitive to chemotherapy. It is shown that HER2 overexpression is observed in 16 % of GC cases. According to the results of a randomized phase III TOGA study, Herceptin (trastuzumab) in addition to combination of capecitabine with cisplatin/fluorouracil as a first-line treatment of metastatic HER2-positive GC resulted in increase of median survival from 11,1 to 13,8 months (p = 0,0046), increase of objective response - from 35 to 47 % (p = 0,00175), and increase of median progression-free survival - from 5,5 to 6,7 months (p = 0,0002) compared to single chemotherapy in this regimen. An example of a successful treatment of 71-year-old patient with metastatic HER2-positive gastric cancer, burdened by cardiovascular disease, using the combination of Herceptin, cisplatin and capecitabine is presented. As a result of the treatment, partial tumor regression lasting 36 months was achieved. Overall survival was 76 + months.
Keywords
Full Text
References
- Garcia M., Jemal A., Ward E.M., et al. Global cancer facts and figure 2007. Atlanta, GA: American Cancer Society, 2007.
- Статистика злокачественных новообразований в России и странах СНГ в 2008 г. / Под ред. М.И. Давыдова, Е.М. Аксель. М., 2010.
- Kim N.K., Park Y.S., Heo D.S., et al. A phase iii randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-18.
- Vanhoefer U.V., Rougier P., Wilke H., et al. Final Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57.
- Webb A., Cunningham D., Scarffe J.H., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15:261-67.
- Dank M., Zaluski J., Baorone C., et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/ folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23:16S.
- Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006;24:4991-97.
- Cunningham D., Rao S., Starling N., et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006;24:18S.
- Park Y.H., Lee J.L., Ryoo B.Y., et al. Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol 2008;61(4):623-29.
- Hofmann M., Stoss O., Shi D., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
- Jorgensen J. Targeted HER2 Treatment in Advanced Gastric Cancer. Oncology 2010;78:26-33.
- Bang Y.-J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
Supplementary files
